On this page
Ciprofloxacin Hydrochloride
Overview
Active ingredients
Source: NDC Directory| Ingredient | Strength | RxCUI | Monograph |
|---|---|---|---|
| Ciprofloxacin Hydrochloride | 3 mg/mL | 309309 | View |
Forms, strengths and routes
Source: NDC DirectoryPharmacologic classes are listed in the class section below.
Pharmacologic class
Source: NDC Directory| Class | Type | Browse |
|---|---|---|
| Cytochrome P450 1A2 Inhibitors [MoA] | MoA | All 31 members |
| Fluoroquinolone Antibacterial [EPC] | EPC | All 20 members |
| Fluoroquinolones [CS] | CS | All 20 members |
| Quinolone Antimicrobial [EPC] | EPC | All 16 members |
| Quinolones [CS] | CS | All 16 members |
Regulatory status
Source: Drugs@FDANDC Directory| Product | Trade name | Form | Strength | Ingredient | Status | TE | Flags |
|---|---|---|---|---|---|---|---|
| 019992-001 | CILOXAN | SOLUTION/DROPS | CIPROFLOXACIN HYDROCHLORIDE | Prescription | AT | RLD RS |
Therapeutic equivalence
Source: Orange BookWhat this rating means: Therapeutically equivalent — bioequivalence demonstrated (topical dermatological products)
Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.
Approval history
Source: Drugs@FDA| Type | No. | Action | Status | Date | Review |
|---|---|---|---|---|---|
| Supplement | 26 | Labeling | Approved | March 21, 2017 | Standard |
| Supplement | 20 | Labeling | Approved | February 7, 2006 | Standard |
| Supplement | 19 | Labeling | Approved | August 20, 2004 | Standard |
| Supplement | 16 | Manufacturing (CMC) | Approved | March 13, 2002 | Standard |
| Supplement | 15 | Manufacturing (CMC) | Approved | September 14, 2001 | Standard |
| Supplement | 14 | Manufacturing (CMC) | Approved | March 16, 2001 | Standard |
| Supplement | 13 | Manufacturing (CMC) | Approved | February 18, 2000 | Standard |
| Supplement | 8 | Manufacturing (CMC) | Approved | November 9, 1999 | Standard |
| Supplement | 12 | Manufacturing (CMC) | Approved | August 17, 1999 | Standard |
| Supplement | 10 | Manufacturing (CMC) | Approved | March 11, 1999 | Standard |
| Supplement | 11 | Manufacturing (CMC) | Approved | February 5, 1999 | Standard |
| Supplement | 9 | Manufacturing (CMC) | Approved | October 14, 1998 | Standard |
| Supplement | 7 | Manufacturing (CMC) | Approved | January 15, 1998 | Standard |
| Supplement | 6 | Manufacturing (CMC) | Approved | November 1, 1995 | Standard |
| Supplement | 5 | Manufacturing (CMC) | Approved | November 1, 1995 | Standard |
| Supplement | 4 | Efficacy | Approved | October 27, 1994 | Standard |
| Supplement | 2 | Manufacturing (CMC) | Approved | October 27, 1993 | Standard |
| Supplement | 3 | Manufacturing (CMC) | Approved | January 22, 1993 | Standard |
| Supplement | 1 | Manufacturing (CMC) | Approved | February 12, 1992 | Standard |
| Original application | 1 | Type 3 - New Dosage Form | Approved | December 31, 1990 | Standard |
Prescribing information
Source: openFDA Drug LabelingReproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20260327). This is the manufacturer's labelling text, not a summary and not advice.
Indications and Usage
openFDA Drug LabelingINDICATIONS AND USAGE Ciprofloxacin Hydrochloride Ophthalmic Solution is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions listed below: Corneal Ulcers: Pseudomonas aeruginosa Serratia marcescens* Staphylococcus aureus Staphylococcus epidermidis Streptococcus pneumoniae Streptococcus (Viridans Group)* Conjunctivitis: Haemophilus influenzae Staphylococcus aureus Staphylococcus epidermidis Streptococcus pneumoniae *Efficacy for this organism was studied in fewer than 10 infections.
Dosage and Administration
openFDA Drug LabelingDOSAGE AND ADMINISTRATION: Corneal Ulcers: The recommended dosage regimen for the treatment of corneal ulcers is two drops into the affected eye every 15 minutes for the first six hours and then two drops into the affected eye every 30 minutes for the remainder of the first day. On the second day, instill two drops in the affected eye hourly. On the third through the fourteenth day, place two drops in the affected eye every four hours. Treatment may be continued after 14 days if corneal re-epithelialization has not occurred. Bacterial Conjunctivitis: The recommended dosage regimen for the treatment of bacterial conjunctivitis is one or two drops instilled into the conjunctival sac(s) every two hours while awake for two days and one or two drops every four hours while awake for the next five days.
Contraindications
openFDA Drug LabelingCONTRAINDICATIONS: A history of hypersensitivity to ciprofloxacin or any other component of the medication is a contraindication to its use. A history of hypersensitivity to other quinolones may also contraindicate the use of ciprofloxacin.
Warnings
openFDA Drug LabelingWARNINGS: NOT FOR INJECTION INTO THE EYE. Serious and occasionally fatal hypersensitivity (anaphylactic) reactions, some following the first dose, have been reported in patients receiving systemic quinolone therapy. Some reactions were accompanied by cardiovascular collapse, loss of consciousness, tingling, pharyngeal or facial edema, dyspnea, urticaria, and itching. Only a few patients had a history of hypersensitivity reactions. Serious anaphylactic reactions require immediate emergency treatment with epinephrine and other resuscitation measures, including oxygen, intravenous fluids, intravenous antihistamines, corticosteroids, pressor amines and airway management, as clinically indicated. Remove contact lenses before using.
Adverse Reactions
openFDA Drug LabelingADVERSE REACTIONS: The most frequently reported drug related adverse reaction was local burning or discomfort. In corneal ulcer studies with frequent administration of the drug, white crystalline precipitates were seen in approximately 17% of patients (see PRECAUTIONS ). Other reactions occurring in less than 10% of patients included lid margin crusting, crystals/scales, foreign body sensation, itching, conjunctival hyperemia and a bad taste following instillation. Additional events occurring in less than 1% of patients included corneal staining, keratopathy/keratitis, allergic reactions, lid edema, tearing, photophobia, corneal infiltrates, nausea and decreased vision. To report SUSPECTED ADVERSE REACTIONS, contact Sandoz Inc., at 1-800-525-8747 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Drug Interactions
openFDA Drug LabelingDrug Interactions: Specific drug interaction studies have not been conducted with ophthalmic ciprofloxacin. However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, enhance the effects of the oral anticoagulant, warfarin, and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving cyclosporine concomitantly.
Description
openFDA Drug LabelingDESCRIPTION Ciprofloxacin Hydrochloride Ophthalmic Solution is a synthetic, sterile, multiple dose, antimicrobial for topical ophthalmic use. Ciprofloxacin is a fluoroquinolone antibacterial active against a broad spectrum of gram-positive and gram-negative ocular pathogens. It is available as the monohydrochloride monohydrate salt of 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinoline-carboxylic acid. It is a faint to light yellow crystalline powder with a molecular weight of 385.8. Its empirical formula is C 17 H 18 FN 3 O 3 •HCl•H 2 O and its chemical structure is as follows: Ciprofloxacin differs from other quinolones in that it has a fluorine atom at the 6-position, a piperazine moiety at the 7-position, and a cyclopropyl ring at the 1-position. Each mL of Ciprofloxacin Hydrochloride Ophthalmic Solution contains: Active: ciprofloxacin HCl 3.5 mg equivalent to 3 mg base. Preservative: benzalkonium chloride 0.006%. Inactive: sodium acetate, acetic acid, mannitol 4.6%, edetate disodium 0.05%, hydrochloric acid and/or sodium hydroxide (to adjust pH) and purified water. The pH is approximately 4.5 and the osmolality is approximately 300 mOsm. chemical
Overdosage
openFDA Drug LabelingOVERDOSAGE A topical overdose of Ciprofloxacin Hydrochloride Ophthalmic Solution may be flushed from the eye(s) with warm tap water.
How Supplied / Storage and Handling
openFDA Drug LabelingHOW SUPPLIED: As a sterile ophthalmic solution in Alcon’s DROP-TAINER ® dispensing system consisting of a natural low density polyethylene bottle and dispensing plug and tan polypropylene closure. Tamper evidence is provided with a shrink band around the closure and neck area of the package. NDC: 70518-1170-00 NDC: 70518-1170-01 PACKAGING: 1 in 1 CARTON, 5 mL in 1 BOTTLE PLASTIC PACKAGING: 1 in 1 CARTON, 2.5 mL in 1 BOTTLE PLASTIC Storage: Store at 2°C to 25°C (36°F - 77°F). Protect from light. Repackaged and Distributed By: Remedy Repack, Inc. 625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762
Adverse event reports
Source: openFDA FAERSAttributed to this product's most-reported active ingredient: CIPROFLOXACIN HYDROCHLORIDE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.
Recalls
Source: FDA Enforcement| Classification | Reported | Firm | Reason | Status |
|---|---|---|---|---|
| Class II | June 15, 2022 | Mckesson Medical-Surgical Inc. Corporate Office | cGMP deviations: Temperature abuse | Terminated |
Packaging and NDCs
Source: NDC Directory| Package NDC | Product NDC | Labeler | Description | Marketing start |
|---|---|---|---|---|
| 50090-0882-0 | 50090-0882 | A-S Medication Solutions | 1 BOTTLE, PLASTIC in 1 CARTON (50090-0882-0) / 5 mL in 1 BOTTLE, PLASTIC | November 28, 2014 |
| 50090-1754-0 | 50090-1754 | A-S Medication Solutions | 1 BOTTLE, PLASTIC in 1 CARTON (50090-1754-0) / 2.5 mL in 1 BOTTLE, PLASTIC | March 20, 2015 |
| 76420-942-03 | 76420-942 | Asclemed USA, Inc. | 1 BOTTLE, PLASTIC in 1 CARTON (76420-942-03) / 2.5 mL in 1 BOTTLE, PLASTIC | March 29, 2025 |
| 76420-942-05 | 76420-942 | Asclemed USA, Inc. | 1 BOTTLE, PLASTIC in 1 CARTON (76420-942-05) / 5 mL in 1 BOTTLE, PLASTIC | March 29, 2025 |
| 76420-942-10 | 76420-942 | Asclemed USA, Inc. | 1 BOTTLE, PLASTIC in 1 CARTON (76420-942-10) / 10 mL in 1 BOTTLE, PLASTIC | March 29, 2025 |
| 68071-3351-3 | 68071-3351 | NuCare Pharmaceuticals,Inc. | 10 mL in 1 BOX (68071-3351-3) | July 20, 2017 |
| 68071-4139-5 | 68071-4139 | NuCare Pharmaceuticals,Inc. | 5 mL in 1 BOX (68071-4139-5) | November 1, 2017 |
| 68071-4235-3 | 68071-4235 | NuCare Pharmaceuticals,Inc. | 2.5 mL in 1 BOX (68071-4235-3) | January 17, 2018 |
| 68788-8198-5 | 68788-8198 | Preferred Pharmaceuticals Inc. | 1 BOTTLE, PLASTIC in 1 CARTON (68788-8198-5) / 5 mL in 1 BOTTLE, PLASTIC | May 23, 2022 |
| 63187-985-05 | 63187-985 | Proficient Rx LP | 1 BOTTLE, PLASTIC in 1 CARTON (63187-985-05) / 5 mL in 1 BOTTLE, PLASTIC | March 1, 2018 |
| 63187-985-10 | 63187-985 | Proficient Rx LP | 1 BOTTLE, PLASTIC in 1 CARTON (63187-985-10) / 10 mL in 1 BOTTLE, PLASTIC | December 1, 2018 |
| 70518-1170-0 | 70518-1170 | REMEDYREPACK INC. | 1 BOTTLE, PLASTIC in 1 CARTON (70518-1170-0) / 5 mL in 1 BOTTLE, PLASTIC | May 15, 2018 |
| 67296-0142-1 | 67296-0142 | Redpharm Drug | 1 BOTTLE, PLASTIC in 1 CARTON (67296-0142-1) / 5 mL in 1 BOTTLE, PLASTIC | May 7, 2004 |
| 67296-0142-2 | 67296-0142 | Redpharm Drug | 2 BOTTLE, PLASTIC in 1 CARTON (67296-0142-2) / 5 mL in 1 BOTTLE, PLASTIC | May 7, 2004 |
| 61314-656-05 | 61314-656 | Sandoz Inc | 1 BOTTLE, PLASTIC in 1 CARTON (61314-656-05) / 5 mL in 1 BOTTLE, PLASTIC | May 7, 2004 |
| 61314-656-10 | 61314-656 | Sandoz Inc | 1 BOTTLE, PLASTIC in 1 CARTON (61314-656-10) / 10 mL in 1 BOTTLE, PLASTIC | May 7, 2004 |
| 61314-656-25 | 61314-656 | Sandoz Inc | 1 BOTTLE, PLASTIC in 1 CARTON (61314-656-25) / 2.5 mL in 1 BOTTLE, PLASTIC | May 7, 2004 |
| 50090-0882 | 50090-0882 | A-S Medication Solutions | — | May 7, 2004 |
| 50090-1754 | 50090-1754 | A-S Medication Solutions | — | May 7, 2004 |
| 76420-942 | 76420-942 | Asclemed USA, Inc. | — | May 7, 2004 |
| 68071-3351 | 68071-3351 | NuCare Pharmaceuticals,Inc. | — | May 7, 2004 |
| 68071-4139 | 68071-4139 | NuCare Pharmaceuticals,Inc. | — | May 7, 2004 |
| 68071-4235 | 68071-4235 | NuCare Pharmaceuticals,Inc. | — | May 7, 2004 |
| 68788-8198 | 68788-8198 | Preferred Pharmaceuticals Inc. | — | May 23, 2022 |
| 63187-985 | 63187-985 | Proficient Rx LP | — | May 7, 2004 |
| 70518-1170 | 70518-1170 | REMEDYREPACK INC. | — | May 15, 2018 |
| 67296-0142 | 67296-0142 | Redpharm Drug | — | May 7, 2004 |
| 61314-656 | 61314-656 | Sandoz Inc | — | May 7, 2004 |
Sources for this page
| Dataset | Agency | Used for |
|---|---|---|
| NDC Directory | FDA | Identity, ingredients, strengths, forms, routes, labelers, packages |
| Drugs@FDA | FDA | Application, sponsor, submissions, review documents, marketing status |
| Orange Book | FDA | Therapeutic equivalence codes, reference drug flags, patents, exclusivity |
| Drug Labeling | FDA / NLM | Prescribing information reproduced above |
| FAERS | FDA | Adverse event report counts |
| Enforcement | FDA | Recall records |
Generated September 25, 2026 · 13 sections on this page.